This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this study is to develop an effective form of active specific immunotherapy for prostate cancer based on the fundamental principles of T lymphocyte activation and molecular mechanism of antigen processing and presentation. The project is based upon the hypothesis that antigen presenting cells (APC) grown from prostate cancer patients will be able to successfully present the prostate specific membrane antigen derived peptides to cytotoxic T lymphocyte precursors to induce a specific CTL response in in vitro co-cultures. The idea is to develop an in vitro model system consisting of prostate cancer patients who are HLA A2+ and who have very high levels of serum prostate specific antigen (PSA). The question is whether or not it is possible to induce a peptide specific CTL response in vitro, by presenting one of four PSA gene derived epitopes, exhibiting binding motif for HLA A2 molecules, on autologous APC.
Showing the most recent 10 out of 638 publications